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The adrenal gland is a common site of cancer metastasis. Surgery remains a mainstay
of treatment for solitary adrenal metastasis. For patients who cannot undergo surgery,
radiation is an alternative option. Stereotactic body radiotherapy (SBRT) is an ablative
treatment option allowing larger doses to be delivered over a shorter period of time. In this
study, we report on our experience with the use of SBRT to treat adrenal metastases using
CyberKnife technology. We retrospectively reviewed the Winthrop University radiation
oncology data base to identify 14 patients for whom SBRT was administered to treat
malignant adrenal disease. Of the factors examined, the biological equivalent dose (BED)
of radiation delivered was found to be the most important predictor of local adrenal tumor
control. We conclude that CyberKnife-based SBRT is a safe, non-invasive modality that
has broadened the therapeutic options for the treatment of isolated adrenal metastases.
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Introduction
The adrenal gland is a common site of cancer metastasis. In an autopsy series involving 91 patients
with metastatic cancer, metastatic spread to the adrenal gland was demonstrated in 30% of patients
(1). This propensity for adrenal metastasis, exhibited by many different primary tumor types, is
likely a consequence of the adrenal glands’ rich sinusoidal blood supply (2). Lung cancer, the most
prevalent form ofmetastatic cancer, is themost common primary tumor type responsible for adrenal
metastases (1, 3). Themajority of adrenal metastases are accounted for by lung (35%), gastric (14%),
esophageal (12%), and hepatobiliary (10%) primary carcinomas (3).
The adrenal gland is made up of adrenal cortex and medulla. The adrenal cortex consists of
the zona glomerulosa, which secretes mineralocorticoids (aldosterone), which regulate sodium and
potassium homeostasis. The zona fasciculata secretes glucocorticoids (most importantly, cortisol).
The zona reticularis secretes sex steroids (primarily androgens). The adrenal medulla synthesizes
and secretes catecholamines, which modulate the body’s sympathetic response to stress. The symp-
toms and signs of adrenal insufficiency depend upon the rate and extent of loss of adrenal function,
whether mineralocorticoid production is preserved, and the degree of stress. The onset of adrenal
insufficiency is often very gradual and itmay go undetected until an illness or other stress precipitates
adrenal crisis.
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Clinical manifestations of adrenal insufficiency include
weakness, fatigue, anorexia, nausea, vomiting, constipation,
hyperpigmentation, hypotension, vitiligo, electrolyte disturbances
(hyponatremia, hyperkalemia, hypercalcemia), azotemia, anemia,
and eosinophilia. In severe cases, it can lead to shock and death.
Even though surgery still remains a curative option for iso-
lated adrenal metastasis, it can have its own complications like
longer hospital stay, perioperative complications, and adrenal
insufficiency.
Adrenal gland is located near critical organs, such as stomach,
duodenum, small and large bowels, kidneys, spinal cord, liver,
one should take into consideration tolerance of these organs in
the treatment of adrenal tumors. Rigorous accounting of organ
motion is also mandatory to ensure accurate radiotherapy of the
adrenal gland. Adrenal function preservation is an added benefit
of stereotactic body radiotherapy (SBRT) when compared to
surgery.
With modern imaging technologies, the adrenal gland is often
found to be a solitary site of metastatic disease. In such cases,
surgical resection has often been pursued as definitive therapy. As
reported by Lo et al., curative resection of solitary adrenal metas-
tases resulted in overall survival rates of 73% at 1 year and 40%
at 2 years (4). Focusing exclusively on non-small cell lung cancer
(NSCLC) with solitary adrenal metastases, Tanvetyanon et al.
demonstrated 5-year survival rates of 25% following resection of
isolated synchronous adrenal metastases and 26% after resection
ofmetachronous adrenal metastases (5). Complication rates rang-
ing from9 to 20%have been observed in series of patients reported
to have undergone adrenalectomy in the management of solitary
adrenal metastasis (6–13).
Conventional external beam radiotherapy has been considered
an unreliable alternative to surgical resection for the definitive
management of solitary adrenal metastases because treatment
responses are typically transient and incomplete (6–20). In addi-
tion, conventional radiotherapy cannot compensate for tumor
motion. In a study of 14 patients with adrenalmetastases receiving
radiation doses ranging from 16 to 60Gy, Soejima et al. reported
a 6-month survival of 28.6 and 12.5% among the symptomatic
group. Despite the poor response, conventional radiation may
still prove efficacious for the palliation of pain related to adrenal
metastasis (16). However, SBRT has more recently been intro-
duced as a more reliable treatment for the control of the erad-
ication of adrenal metastasis (12). It exploits the more potent
radiobiological effect of hypofractionation, larger doses given over
a shorter period of time. SBRT precision allows the delivery of
ablative doses of radiation to tissue within the planning target
volume with small margins to minimize the impact on normal
tissue (19). At our institution, the CyberKnife, a robotic-based
SBRT delivery system which accounts for intrafraction tumor
motion, has been in use since 2005 (19, 20).
One of the advantages of the CyberKnife is the ability to contin-
uously track, in real time the movement of a tumor or target with
respiration. Katoh et al. (21) showed that adrenal tumors canmove
up to 6.1, 11.1, and 7.0mm in the left-right, craniocaudal, and
anterior–posterior directions, respectively. Given the doses used,
and the sensitivity of the surrounding anatomy, having the ability
to track a tumor that moves during respiration, such as an adrenal
tumors or lung tumors is imperative in delivering an ablative dose
of radiation without either missing the tumor or damaging sur-
rounding anatomy. This study reports on our experience utilizing
this technology to treat malignant adrenal disease.
Materials and Methods
Study Design
We utilized an Institutional Review Board approved database to
retrospectively identify 14 patients for whom SBRT was adminis-
tered to treat malignant adrenal disease from 2006 to 2011. Charts
were reviewed to determine patient characteristics, treatment
details, and outcomes. Primary study endpoints were treatment
response, duration of response, and survival time measured from
the initiation of SBRT. Treatment response was assessed on the
basis of routine follow-up imaging studies with CT or PET/CT
scan. Local treatment failure was defined as any radiographic pro-
gression of adrenal tumor. Distant failure was defined as the devel-
opment of newmetastases or progression of untreatedmetastases.
All patients were treated with SBRT delivered via CyberKnife
(Accuray Corporation; Sunnyvale, CA, USA) technology.
All tumors were treated using a CyberKnife robotic linear
accelerator. All patients were immobilized using a thermoplastic
cast with arms up. One fiducial marker was placed at least 5 days
prior under CT guidance by an Interventional Radiologist to
account for seed migration. CT imaging was performed using
1.5mm cuts with and without contrast. At this institution, which
as per NCCN guidelines regarding the use of hypofractionated
SBRT has appropriate technology, physics, and clinical expertise,
all treatments have been given safely and without difficulty. It is
important, however, that this expertise be readily available at all
times regarding the delivery of this form of treatment given the
complexity involved.
Planning was performed using Multiplan (Accuray, Inc., Sun-
nyvale, CA, USA) inverse planning and delivered using the
CyberKnife (Accuray, Inc.) with motion and respiratory tracking
performed using the Synchrony system (Accuray, Inc.) Only the
adrenal tumor was treated rather than the whole gland (Figure 1).
Results
Patient Characteristics
Patient and tumor characteristics are summarized in Table 1.
Median age was 65 years (range, 49–91 years). Primary tumor sites
included non-small cell lung (n= 6), renal cell (n= 2), melanoma
(n= 1), primary adrenal (n= 1), mixed Mullerian (n= 1), GE
junction (n= 1), bladder (n= 1), and lymphoma (n= 1). Five
patients were found to have adrenal involvement at their original
cancer diagnosis. For the nine remaining patients, the median
interval from first cancer diagnosis to the clinical detection of
adrenal metastasis was 14months (range 8–56). Two patients
had pain associated with adrenal metastases in the setting of
widespread metastatic disease and received SBRT with palliative
intent. Their pain markedly improved after treatment. The other
12 patients had no other sites of active metastasis and received
SBRT with definitive intent. These patients did not receive any
concurrent chemotherapy while getting CyberKnife.
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TABLE 1 | Patient characteristics and outcome.
Patient Age Gender Primary tumor Outcome post CK Time to local failure (months) Time from CK to death (months)
1 62 M NSCLC Stable 7 11
2 91 M RCC Regression +38 NA (still alive)
3 64 M NSCLC Stable 2 (until death) 2
4 49 F NSCLC Progression 0 NA (still alive)
5 59 M NSCLC Stable 5 7
6 63 M DLBCL Complete response +3 NA (still alive)
7 68 M Melanoma Regression 4 (until death) 4
8 49 F RCC Regression 14 (until death) 14
9 70 F Adrenocortical carcinoma Stable 4 11
10 66 F MMT NA NA 9
11 75 F NSCLC NA NA 3
12 71 M NSCLC Progression 0 3
13 60 M GE junction adenocarcinoma Regression 11 (until death) 11
14 83 M Urothelial carcinoma NA NA 1
CK, CyberKnife; NSCLC, non-small cell lung cancer; RCC, renal cell carcinoma; DLBCL, diffuse large B cell lymphoma; MMT, mixed Mullerian tumor; GE junction, gastroesophageal.
TABLE 2 | Delivered SBRT regimens and calculated BEDs.
Patient Time Dose (cGy) #fx BED (cGy) 180cGy Eq
1 0 3000 3 6000 5085
2 56 3000 3 6000 5085
3 12 2750 5 4263 3612
4 12 2500 5 3750 3178
5 14 2100 3 3570 3025
6 0 2500 5 3750 3178
7 31 2400 3 4320 3661
8 24 3000 3 6000 5085
9 0 2000 5 2800 2373
10 8 2500 5 3750 3178
11 12 2400 3 4320 3661
12 13 2500 5 3750 3178
13 16 2400 3 4320 3661
14 19 1300 1 2990 2534
SBRT Treatment Plans and Delivered Biological
Equivalent Doses
Individualized SBRT treatment schedules and calculated biologi-
cal equivalent dose (BED) are shown in Table 2. With the excep-
tion of 1 patient with primary bladder cancer receiving 1300 cGy
in a single treatment fraction, the remaining 13 patients received
a total of either 3 or 5 fractions with each fraction ranging from
500 to 1000 cGy. This heterogeneity in treatment delivery led to
a wide range of delivered BEDs (2990–6000 cGy), assuming an
alpha/beta ratio of 10.
Local Adrenal Tumor Control
There was considerable variation in calculated BEDs (range
4667–13,000 cGy). BED was the most important predictor of
local adrenal tumor control. According to best adrenal tumor
response, mean BEDs were 10,053 cGy for radiographic regres-
sion of disease (n= 5); 8115 cGy for stable disease (n= 4), and
6667 cGy for progression of disease (n= 2), p= 0.047. No adrenal
metastases resulting from a solid tumor responded to SBRT
with BED< 8800 cGy and no patient experienced initial adrenal
progression following SBRT with BED> 6667 cGy. Duration of
adrenal tumor control also correlated with calculated mean BED,
which was 9676 cGy for never locally failing (n= 6) and 7600 cGy
TABLE 3 | Characteristics of previous studies using SBRT to treat adrenal
metastases.
Reference/recruitment/
country
No. of
patients
Radiation dose
(median)
Outcome 1year
OS, LC, DC
Chawla et al.
(23)/2001–2007/USA
30 400 cGy10 fx 44%
55%
13%
Katoh et al.*
(21)/2004–2006/Japan
9 600 cGy8 fx 78%
100%
Casamassima et al.
(22)/2002–2009/Italy
48 1200 cGy3 fx 39.7%
90%
9%
Holy et al.
(26)/2002–2009/Germany
18 720 cGy5 fx 23months
77%
Torok et al.
(27)/2002–2009/USA
7 1700 cGy in 1 fx
(1600 cGy in 1 fx and
2700 cGy in 3 fx)
8months
63%
*Katoh reference above includes patients with primary adrenal tumors and metastases.
for ever locally failing tumors (n= 5). However, eventual local
treatment failure was seen in one of three patients receiving even
the highest calculated BED (13,000 cGy).
Toxicity
Nopatient developed renal or adrenal insufficiency and therewere
no bowel or spinal cord injuries.
Literature Review
Several groups have previously reported on their experiences
with SBRT for the definitive treatment of adrenal oligometastases
with conflicting results as summarized in Table 3. For example,
Casamassima et al. at the University of Florence reported an
impressive 90% local control rate at 2 years (22), whereas Chawla
et al. at theUniversity of Rochester reported only a 55%1 year local
control rate (23). These differences may be explained by differ-
ences in SBRT dosing and fractionation accounting for significant
differences in the prescribed BEDs with maximum delivered BED
of 13,730 cGy (36Gy in 3 fractions) in the Florence series, but
just between 2240 cGy (16Gy in 4 fractions) and 7500 cGy (50Gy
in 10 fractions) in the Rochester cohort (22). Other series have
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FIGURE 1 | Fifty-seven-year-old female with metastatic small cell
lung cancer with limited biopsy proven painful recurrence in the
right adrenal gland despite prior systemic therapy. Patient was
treated to the right adrenal metastasis 3000 cGy in three fractions
prescribed to the 82% isodose line. Both kidneys, spinal cord, and regional
bowel were contoured.
suggested that BEDs > 10,000 cGy are required to achieve optimal
local control (24, 25).
In a series fromHokkaidoUniversity, 9 patients with 10 adrenal
lesions were treated with SBRT with a dose of 4800 cGy in 8 frac-
tions. The 1-year overall survival and local control rates were 78
and 100%, respectively (21). In contrast to the other groups, they
included primary adrenal tumors and perirenal metastatic lymph
nodes. In another study by Holy et al., 18 patients with NSCLC
and adrenal metastases treated with definitive SBRT for adrenal
metastases from NSCLC, experienced a median progression free
survival (PFS) of 4.2months. PFS was markedly increased to
12months for 13 patients with isolated adrenal metastases. After
a median follow-up of 21months, 10 of these 13 patients achieved
local control and median overall survival was 23months (26).
These results compare favorably to the surgical series of Porte
et al. where surgical resection of solitary adrenal metastasis was
reported to achieve a median PFS of just 13months (28).
Discussion
Historically, surgery has been the mainstay of treatment for iso-
lated adrenal metastases. In 1982, Twomey et al. documented
prolonged survival following adrenalectomy in the management
of oligometastatic NSCLC (29). Patients with a synchronous
metastasis who underwent adrenalectomy had a shorter over-
all survival than those with metachronous metastasis. Overall,
subsequent long-term disease free survival has been observed
in approximately 25% of patients undergoing resection of soli-
tary adrenal metastasis (6). Long-term survival after resection
of isolated NSCLC adrenal metastases was also demonstrated by
Mercier et al. with an overall 5-year survival rate of 23.3 and 38% if
the isolated adrenalmetastasis occurred 6months after lung resec-
tion (11). In colorectal carcinoma, Katayama et al. reported 5 of
11 patients with adrenal metastases remained alive without signs
of recurrence after adrenalectomy with follow-up times ranging
from 8months to 9 years (30). In renal cell carcinoma, patients
with solitary adrenal metastases achieved a significant tumor
specific survival benefit with a median survival of 68months
compared to patients with additional metastatic sites at the time
of surgery (31).
In this report, we have retrospectively reviewed our institu-
tional database to identify 14 patients for whom SBRTwas admin-
istered to treat malignant adrenal disease from 2006 to 2011.
Of the factors examined, BED was the most important predictor
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of local adrenal tumor control. The duration of adrenal tumor
control correlatedwith calculatedmean BED, whichwas 7600 cGy
for local failures vs. 9676 cGy for those who attained local control.
This finding is supported by other series, which have suggested the
delivery of BEDs > 10,000 cGy to achieve optimal tumor control
(24, 25).Our experiencewith patients treated above and below this
threshold (median BEDof 8460 cGy) also supports the 10,000 cGy
threshold.
We observed an initial tumor control rate of 64% (36% tumor
regression plus 28% stable disease) similar to the 78% (22% regres-
sion plus 56% stable disease) adrenal tumor control rate reported
by Torok et al. (27). These small differences could be explained
by different tumor types in these two reports. Notably, our series
comprises an admixture of different primary tumor types, whereas
Torok et al. included only lung and hepatocellular primary car-
cinomas. In our series, all patients with stable disease following
CyberKnife treatment had primary lung cancers. Notably, Torok
et al. study population predominantly comprised patients with
lung primaries; this could explain the discrepancy in their higher
initial response and difference in patients with stable disease.
The transient nature of prolonged control from metastatic lung
primaries was demonstrated in both studies.
In addition, we also looked at tumor histology as it pre-
dicted for treatment outcome. We had an admixture of different
primaries, but the majority was six patients with NSCLC: four
adenocarcinoma, one squamous cell carcinoma, and one high-
grade sarcoma. The latter two patients progressed after treatment,
which could be attributable to aggressive histology. The three ade-
nocarcinomas remained stable with two eventually progressing
locally at 5 and 7months and one remained stable until failing
distantly at 2months. The fourth patient opted for palliative care,
so no post treatment scans were obtained. Other primaries fared
better with regression in the size of the lesion noted in renal car-
cinoma, GE junction adenocarcinoma, and melanoma. Three of
these patients eventually succumbed to their disease from distant
failure. Complete responsewas documented for diffuse large B cell
lymphoma.
While surgical resection remains a suitable option for patients
with isolated adrenal metastases who are able to undergo that
approach, CyberKnife-based SBRT is a safe, non-invasive alter-
native modality that has broadened the therapeutic options for
the attainment of palliation and local control of this historically
difficult-to-manage patient cohort. When utilized in this setting,
we recommend targeting a BED of at least 10,000 cGy. We also
encourage consideration of this approach in all patients with soli-
tary adrenal metastasis who cannot or will not undergo surgical
resection. Larger series and increased follow-up times will be
required in the future evaluation of this treatment.
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